russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2022-5285russjcardiol-5285Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯGUIDELINES FOR THE PRACTITIONERМедикаментозная терапия артериальной гипертонии и дислипидемии: возможности препарата Липертанс (на примере клинического наблюдения)Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)https://orcid.org/0000-0003-3729-616XКашталапВ. В.KashtalapV. V.

Доктор медицинских наук, доцент, заведующий отделом клинической кардиологии.

Кемерово

Kemerovo

v_kash@mail.ruФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийРоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation202208122022271152855285Copyright © Кашталап В.В., 20222022Кашталап В.В.Kashtalap V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5285

В статье, проиллюстрированной клиническим наблюдением, представлены эпидемиологические данные о высокой распространенности коморбидности артериальной гипертонии и дислипидемии в общей популяции, показана ведущая роль этих ключевых факторов сердечно-сосудистого риска в развитии сердечно-сосудистых осложнений. При этом в рамках первичной профилактики приверженность пациентов к липидснижающему компоненту комплексной терапии остается низкой. Фиксированные комбинации медикаментозной терапии (Липертанс) на основе антигипертензивных (амлодипин, периндоприл) и липидснижающих препаратов (аторвастатин) могут значительно повысить эффективность терапии.

The article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary prevention, the adherence of patients to the lipid-lowering therapy remains low. Fixed-dose combinations (Lipertans) based on antihypertensive (amlodipine, perindopril) and lipid-lowering drugs (atorvastatin) can significantly increase the effectiveness of therapy.

артериальная гипертониядислипидемиясердечно-сосудистый рисккоморбидностьфиксированные комбинацииполитаблеткиhypertensiondyslipidemiacardiovascular riskcomorbidityfixeddose combinationspolypillsReferencesДрапкина О. М., Концевая А. В., Калинина А. М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. doi:10.15829/1728-8800-2022-3235.Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Prevention of chronic noncommunicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) doi:10.15829/1728-8800-2022-3235.Вилков В. Г., Шальнова С. А. Тридцатилетняя динамика распространенности кардиометаболических факторов риска в популяциях Российской Федерации и Соединенных Штатов Америки. Кардиоваскулярная терапия и профилактика. 2022;21(8):3304. doi:10.15829/1728-8800-2022-3304.Vilkov VG, Shalnova SA. Thirty-year dynamics of the prevalence of cardiometabolic risk factors in populations of the Russian Federation and the United States of America. Cardiovascular Therapy and Prevention. 2022;21(8):3304. (In Russ.) doi:10.15829/1728-8800-2022-3304.Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Medicine. 2013;11:177. doi:10.1186/1741-7015-11-177.Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Medicine. 2013;11:177. doi:10.1186/1741-7015-11-177.Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37. doi:10.1038/s41581-019-0244-2.Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37. doi:10.1038/s41581-019-0244-2.Ford ES, Ajani UA, Croft JB, et al. Explaining the Decrease in U. S. Deaths from Coronary Disease, 1980-2000. The New England Journal of Medicine. 2007;356;237:2388-98.Ford ES, Ajani UA, Croft JB, et al. Explaining the Decrease in U. S. Deaths from Coronary Disease, 1980-2000. The New England Journal of Medicine. 2007;356;237:2388-98.Бойцов С. А., Баланова Ю. А., Шальнова С. А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14.Boytsov SA, Balanova YuA, Shalnova SA, et al. on behalf of the ECCD-RF workgroup. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD Cardiovascular Therapy and Prevention, 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.Баланова Ю. А., Шальнова С. А., Имаева А. Э. и др. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная фармакотерапия в кардиологии. 2019;15(4):450-66. doi:10.20996/1819-6446-2019-15-4-450-466.Balanova YuA, Shalnova SA, Imaeva AE, et al. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSERF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450-66. (In Russ.) doi:10.20996/1819-6446-2019-15-4-450-466.Концевая А. В., Шальнова С. А., Драпкина О. М. Исследование ЭССЕ-РФ: эпидемиология и укрепление общественного здоровья. Кардиоваскулярная терапия и профилактика. 2021;20(5):2987. doi:10.15829/1728-8800-2021-2987.Kontsevaya AV, Shalnova SA, Drapkina OM. ESSAY-RF Study: Epidemiology and Public Health Promotion. Cardiovascular Therapy and Prevention. 2021;20(5):2987. (In Russ.) doi:10.15829/1728-8800-2021-2987.Баланова Ю. А., Шальнова С. А., Куценко В. А. и др. от имени участников исследования ЭССЕ-РФ. Вклад артериальной гипертонии и других факторов риска в выживаемость и смертность в российской популяции. Кардиоваскулярная терапия и профилактика. 2021;20(5):3003. doi:10.15829/1728-8800-2021-3003.Balanova YuA, Shalnova SA, Kutsenko VA, et al. on behalf of the participants in the ESSAY-RF study. Contribution of arterial hypertension and other risk factors to survival and mortality in the Russian population. Cardiovascular Therapy and Prevention. 2021;20(5):3003. (In Russ.) doi:10.15829/1728-8800-2021-3003.Муромцева Г. А., Концевая А. В., Константинов В. В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11. doi:10.15829/1728-8800-2014-6-4-11.Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. on behalf of the ECVD-RF study The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention, 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.Бойцов С. А., Драпкина О. М., Шляхто Е. В. и др. Исследование ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021;20(5):3007. doi:10.15829/1728-8800-2021-3007.Boytsov SA, Drapkina OM, Shlyakhto EV, et al. ESSAY-RF study (Epidemiology cardiovascular diseases and their risk factors in the regions of the Russian Federation). Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. (In Russ.) doi:10.15829/1728-8800-2021-3007.Гринштейн Ю. И., Шабалин В. В., Руф Р. Р. и др. Распространенность сочетания артериальной гипертонии и дислипидемии среди взрослого населения крупного Восточносибирского региона. Кардиоваскулярная терапия и профилактика. 2021;20(4):2865. doi:10.15829/1728-88002021-2865.Grinshtein YU, Shabalin VV, Ruf RR, et al. Prevalence of a combination of arterial hypertension and dyslipidemia among adults in the major East Siberian region. Cardiovascular Therapy and Prevention. 2021;20(4):2865. (In Russ.) doi:10.15829/1728-88002021-2865.Dalal JJ, Padmanabhan TN, Jain P, et al. LIPITENSION: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab. 2012;16(2):240-5. doi:10.4103/2230-8210.93742.Dalal JJ, Padmanabhan TN, Jain P, et al. LIPITENSION: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab. 2012;16(2):240-5. doi:10.4103/2230-8210.93742.Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957-67. doi:10.1016/S0140-6736(15)01225-8.Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957-67. doi:10.1016/S0140-6736(15)01225-8.Баланова Ю. А., Концевая А. В., Мырзаматова А. О. и др. Экономический ущерб от артериальной гипертонии, обусловленный ее вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации. Рациональная фармакотерапия в кардиологии. 2020;16(3):415-23. doi:10.20996/1819-6446-2020-05-03.Balanova YuA, Kontsevaya AV, Myrzamatova AO, et al. Economic Burden of Hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020;16(3):415-23. (In Russ.) doi:10.20996/1819-6446-2020-05-03.Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259(24):3579-86. doi:10.1001/jama.259.24.3579.Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259(24):3579-86. doi:10.1001/jama.259.24.3579.Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005;112(22):3384-90. doi:10.1161/CIRCULATIONAHA.105.537472.Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005;112(22):3384-90. doi:10.1161/CIRCULATIONAHA.105.537472.Erhardt L, Moller R, Puig JG. Comprehensive cardiovascular risk management–what does it mean in practice? Vasc Health Risk Manag. 2007;3(5):587-603. Erratum in: Vasc Health Risk Manag. 2008;4(3):741.Erhardt L, Moller R, Puig JG. Comprehensive cardiovascular risk management–what does it mean in practice? Vasc Health Risk Manag. 2007;3(5):587-603. Erratum in: Vasc Health Risk Manag. 2008;4(3):741.Hurtubise J, McLellan K, Durr K, et al. The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis. Curr Atheroscler Rep. 2016;18(12):82. doi:10.1007/ s11883-016-0632-z.Hurtubise J, McLellan K, Durr K, et al. The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis. Curr Atheroscler Rep. 2016;18(12):82. doi:10.1007/ s11883-016-0632-z.Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019;322(14):1381-91. doi:10.1001/jama.2019.14120.Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019;322(14):1381-91. doi:10.1001/jama.2019.14120.Sever PS, Poulter NR, Mastorantonakis S, et al.; ASCOT Investigators. Coronary heart disease benefits from blood pressure and lipid-lowering. Int J Cardiol. 2009;135(2):218-22. doi:10.1016/j.ijcard.2009.01.036.Sever PS, Poulter NR, Mastorantonakis S, et al.; ASCOT Investigators. Coronary heart disease benefits from blood pressure and lipid-lowering. Int J Cardiol. 2009;135(2):218-22. doi:10.1016/j.ijcard.2009.01.036.Williams B, Mancia G, Spiering W, et al.; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. doi:10.1097/HJH.0000000000001940.Williams B, Mancia G, Spiering W, et al.; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. doi:10.1097/HJH.0000000000001940.Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.Dinicolantonio JJ, Lavie CJ, O’Keefe JH. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med. 2013;125(4):154-68. doi:10.3810/pgm.2013.07.2687.Dinicolantonio JJ, Lavie CJ, O’Keefe JH. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med. 2013;125(4):154-68. doi:10.3810/pgm.2013.07.2687.Kes S, Caglar N, Canberk A, et al. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. Curr Med Res Opin. 2003;19(3):226-37. doi:10.1185/030079903125001677.Kes S, Caglar N, Canberk A, et al. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. Curr Med Res Opin. 2003;19(3):226-37. doi:10.1185/030079903125001677.Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vasc Health Risk Manag. 2011;7:777-87. doi:10.2147/VHRM.S17207.Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vasc Health Risk Manag. 2011;7:777-87. doi:10.2147/VHRM.S17207.Bertrand ME, Ferrari R, Remme WJ, et al.; EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010;159(5):795-802. doi:10.1016/j.ahj.2009.12.042.Bertrand ME, Ferrari R, Remme WJ, et al.; EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010;159(5):795-802. doi:10.1016/j.ahj.2009.12.042.Watson S, Gupta A, Poulter NR. Visit-to-visit variability of systolic blood pressure in hypertensive patients treated exlusively with a combination treatment in the AngloScandinvaian Cardiac Outcomes Trial-BPLA. J Hypertens. 2014;32(e-suppl 1):e125.9C.06.Watson S, Gupta A, Poulter NR. Visit-to-visit variability of systolic blood pressure in hypertensive patients treated exlusively with a combination treatment in the AngloScandinvaian Cardiac Outcomes Trial-BPLA. J Hypertens. 2014;32(e-suppl 1):e125.9C.06.Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009;9(3):135-42. doi:10.1007/BF03256570.Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009;9(3):135-42. doi:10.1007/BF03256570.Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017;33(10):1783-7. doi:10.1080/03007995.2017.1367275.Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017;33(10):1783-7. doi:10.1080/03007995.2017.1367275.Vlachopoulos C, Grammatikou V, Kallistratos M, Karagiannis A. Effectiveness of perindopril/amlodipine fixed dose combination in everyday clinical practice: results from the EMERALD study. Curr Med Res Opin. 2016;32(9):1605-10. doi:10.1080/03007995.2016.1193481.Vlachopoulos C, Grammatikou V, Kallistratos M, Karagiannis A. Effectiveness of perindopril/amlodipine fixed dose combination in everyday clinical practice: results from the EMERALD study. Curr Med Res Opin. 2016;32(9):1605-10. doi:10.1080/03007995.2016.1193481.Castellano JM, Pocock SJ, Bhatt DL, et al.; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.Castellano JM, Pocock SJ, Bhatt DL, et al.; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.Shepherd J, Kastelein JJ, Bittner V, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51(15):1448-54. doi:10.1016/j.jacc.2007.11.072.Shepherd J, Kastelein JJ, Bittner V, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51(15):1448-54. doi:10.1016/j.jacc.2007.11.072.Berwanger O, Santucci EV, de Barros E Silva PGM, et al.; SECURE-PCI Investigators. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA. 2018;319(13):1331-40. doi:10.1001/jama.2018.2444.Berwanger O, Santucci EV, de Barros E Silva PGM, et al.; SECURE-PCI Investigators. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA. 2018;319(13):1331-40. doi:10.1001/jama.2018.2444.Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. doi:10.1056/NEJMoa040583.Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. doi:10.1056/NEJMoa040583.Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;ehac015. doi:10.1093/eurheartj/ehac015.Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;ehac015. doi:10.1093/eurheartj/ehac015.Galicia-Garcia U, Jebari S, Larrea-Sebal A, et al. Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. Int J Mol Sci. 2020;21(13):4725. doi:10.3390/ijms21134725.Galicia-Garcia U, Jebari S, Larrea-Sebal A, et al. Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. Int J Mol Sci. 2020;21(13):4725. doi:10.3390/ijms21134725.Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and doseresponse meta-analyses. BMJ. 2021;374:n1537. doi:10.1136/bmj.n1537.Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and doseresponse meta-analyses. BMJ. 2021;374:n1537. doi:10.1136/bmj.n1537.Ray KK, Molemans B, Schoonen WM, et al.; DA VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279-89. doi:10.1093/eurjpc/zwaa047.Ray KK, Molemans B, Schoonen WM, et al.; DA VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279-89. doi:10.1093/eurjpc/zwaa047.Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061-8. doi:10.1161/01.CIR.0000140261.58966.A.Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061-8. doi:10.1161/01.CIR.0000140261.58966.A.Ерина А. М., Усольцев Д. А., Бояринова М. А. и др. Потребность в назначении гиполипидемической терапии в российской популяции: сравнение шкал SCORE и SCORE2 (по данным исследования ЭССЕ-РФ). Российский кардиологический журнал. 2022;27(5):5006. doi:10.15829/1560-4071-2022-5006. EDN HBBGKQ.Erina AM, Usoltsev DA, Boyarinova MA, et al. Appointment of lipid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSERF study). Russian Journal of Cardiology. 2022;27(5):5006. (In Russ.) doi:10.15829/1560-4071-2022-5006. EDN HBBGKQ.Кавешников В. С., Серебрякова В. Н., Трубачева И. А. Детерминанты контроля артериальной гипертонии в гипертензивной популяции, получающей медикаментозную терапию. Комплексные проблемы сердечно-сосудистых заболеваний. 2022;11(1):26-35. doi:10.17802/2306-1278-2022-11-1-26-35.Kaveshnikov VS, Serebryakova VN, Trubacheva IA. Determinants of arterial hypertension control in the hypertensive population receiving medical therapy. Complex Issues of Cardiovascular Diseases. 2022;11(1):26-35. (In Russ.) doi:10.17802/2306-1278-2022-11-1-26-35.Simon A, Dézsi CA. Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study. Adv Ther. 2019;36(8):2010-0. doi:10.1007/s12325-019-01002-8.Simon A, Dézsi CA. Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study. Adv Ther. 2019;36(8):2010-0. doi:10.1007/s12325-019-01002-8.Ежов М.В., Кухарчук В.В., Сергиенко И.В. и др. Существующие проблемы и новые возможности в лечении дислипидемий. Совместное заключение по итогам Экспертного совета. Рациональная Фармакотерапия в Кардиологии. 2021;17(1):169-72. doi:10.20996/1819-6446-2021-02-02.Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Existing problems and new possibilities in the treatment of dyslipidemia. Joint Conclusion Based on the Results of the Expert Council. Rational Pharmacotherapy in Cardiology. 2021;17(1):169-72. (In Russ.) doi:10.20996/1819-6446-2021-02-02.

The authors declare that there are no conflicts of interest present.